Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men
Author:
Palaniswami Paari M1, El Sayed Ahmed1, Asriel Benjamin1, Carollo Jesse R1, Fierer Daniel S1, Akil Bisher, Bailey Juan, Bellman Paul, Bowers Daniel, Bungay Krisczar, Burger Susanne, Cantor Aviva, Chasan Rachel, Chavez Robert, Chow Rita, Cohen Robert, Dalton Patrick, Dellosso John, Dillon Stephen, Donlon Eileen, Farrow Terry, Fefer Jose, Gaisa Michael, Guadron Rodolfo, Haber Stuart, Hefron Susan, Higgins Lawrence, Hitzeman Lawrence, Hsu Ricky, Huprikar Shirish, Inada Victor, Jacob Sneha, Johnson Livette, Johnston Barbara, Kaminsky Donald, Klein Oscar, Kwong Jeffrey, Lares-Guia Jose, Leach Eric, Levine Randy, Linetskaya Irina, Litvinova Larisa, Malhotra Amisha, Mandell William, Markowitz Martin, Mayer Gal, Meraz Eddie, Mortensen Erik, Olivieri Joseph, Paolino Charles, Photangtham Punyadech, Psevdos George, Radix Asa, Rapaport Steven, Ray Roona, Rodriguez-Caprio Gabriela, Shay William, Somasundaram Nirupama, Sorra Lembitu, Tran Richie, Urbina Antonio, Vail Rona, Wallach Francis, Wang Wen, Weiss Susan, Wiener Melissa,
Affiliation:
1. Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
Abstract
Abstract
Background
Treatment of HIV-infected men during early hepatitis C virus (HCV) infection with interferon results in a higher cure rate with a shorter duration of treatment than during chronic HCV infection. We recently demonstrated that this phenomenon applied to interferon-free treatment as well, curing most participants with short-course sofosbuvir and ribavirin. Due to the significantly higher potency of the ledipasvir/sofosbuvir (LDV/SOF) combination, we hypothesized that we would be more successful in curing early HCV infections using a shorter course of LDV/SOF than that used for treating chronic HCV infections.
Methods
We performed a prospective, open-label, consecutive case series study of 8 weeks of LDV/SOF in HIV-infected men with early genotype 1 HCV infection. The primary end point was aviremia at least 12 weeks after completion of treatment.
Results
We treated 25 HIV-infected men with early sexually acquired HCV infection with 8 weeks of LDV/SOF, and all 25 (100%) were cured. Twelve (48%) reported sexualized drug use with methamphetamine.
Conclusions
Eight weeks of LDV/SOF cured all 25 HIV-infected men with early HCV infection, including those who were actively using drugs. Based on these results, we recommend treatment of newly HCV-infected men during early infection, regardless of drug use, to both take advantage of this 8-week treatment and to decrease further HCV transmission among this group of men.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Oncology
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|